Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.65 Billion USD | -0.84% |
| 2022 | 5.33 Billion USD | -44.87% |
| 2021 | 9.28 Billion USD | 142.63% |
| 2020 | 3.9 Billion USD | 75.01% |
| 2019 | 2.42 Billion USD | -12.81% |
| 2018 | 2.68 Billion USD | 21.87% |
| 2017 | 2.07 Billion USD | 56.27% |
| 2016 | 1.44 Billion USD | 6.3% |
| 2015 | 1.32 Billion USD | 49.32% |
| 2014 | 876.6 Million USD | 10.32% |
| 2013 | 784.25 Million USD | 66.05% |
| 2012 | 496.66 Million USD | 323.1% |
| 2011 | -170.52 Million USD | -110.48% |
| 2010 | -75.66 Million USD | -62.84% |
| 2009 | -55.36 Million USD | 33.37% |
| 2008 | -61.32 Million USD | 27.48% |
| 2007 | -82.07 Million USD | -13.0% |
| 2006 | -93.06 Million USD | -210.83% |
| 2005 | 139.92 Million USD | 463.35% |
| 2004 | -27.22 Million USD | 70.26% |
| 2003 | -91.51 Million USD | 25.56% |
| 2002 | -113.49 Million USD | -33.96% |
| 2001 | -79.6 Million USD | -463.67% |
| 2000 | -20.85 Million USD | 23.93% |
| 1999 | -20.4 Million USD | -52.86% |
| 1998 | -9.5 Million USD | -4766.67% |
| 1997 | -9.3 Million USD | -90.32% |
| 1996 | -11.2 Million USD | -76.15% |
| 1995 | -1.7 Million USD | 152.0% |
| 1994 | -25 Million USD | 29.97% |
| 1993 | -35.7 Million USD | -119.02% |
| 1992 | -16.3 Million USD | -16.43% |
| 1991 | -8.8 Million USD | -193.33% |
| 1990 | -3 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.21 Billion USD | 39.15% |
| 2024 Q1 | 872.6 Million USD | -21.8% |
| 2024 Q3 | 1.17 Billion USD | 34.12% |
| 2023 Q3 | 1.11 Billion USD | -7.79% |
| 2023 FY | - USD | -0.84% |
| 2023 Q2 | 1.2 Billion USD | 16.8% |
| 2023 Q1 | 1.03 Billion USD | -24.82% |
| 2023 Q4 | 1.26 Billion USD | 13.74% |
| 2022 Q4 | 1.37 Billion USD | -15.18% |
| 2022 Q2 | 1.17 Billion USD | -0.32% |
| 2022 Q1 | 1.17 Billion USD | -53.24% |
| 2022 Q3 | 1.61 Billion USD | 37.88% |
| 2022 FY | - USD | -44.87% |
| 2021 Q1 | 1.33 Billion USD | 7.71% |
| 2021 Q3 | 1.9 Billion USD | -50.39% |
| 2021 Q4 | 2.51 Billion USD | 32.22% |
| 2021 FY | - USD | 142.63% |
| 2021 Q2 | 3.83 Billion USD | 187.51% |
| 2020 Q3 | 1.08 Billion USD | 9.77% |
| 2020 FY | - USD | 75.01% |
| 2020 Q2 | 987.4 Million USD | 35.11% |
| 2020 Q1 | 730.8 Million USD | 8.15% |
| 2020 Q4 | 1.23 Billion USD | 14.35% |
| 2019 FY | - USD | -12.81% |
| 2019 Q4 | 675.7 Million USD | -18.51% |
| 2019 Q3 | 829.2 Million USD | 191.15% |
| 2019 Q2 | 284.8 Million USD | -52.91% |
| 2019 Q1 | 604.8 Million USD | -15.78% |
| 2018 Q4 | 718.1 Million USD | 5.79% |
| 2018 FY | - USD | 21.87% |
| 2018 Q3 | 678.79 Million USD | 9.1% |
| 2018 Q2 | 622.18 Million USD | -0.96% |
| 2018 Q1 | 628.19 Million USD | 16.59% |
| 2017 Q1 | 477.9 Million USD | 37.72% |
| 2017 FY | - USD | 56.27% |
| 2017 Q3 | 609.5 Million USD | 7.61% |
| 2017 Q4 | 538.81 Million USD | -11.6% |
| 2017 Q2 | 566.37 Million USD | 18.51% |
| 2016 Q4 | 347 Million USD | -11.17% |
| 2016 Q1 | 352.28 Million USD | 52.45% |
| 2016 Q2 | 316.65 Million USD | -10.11% |
| 2016 FY | - USD | 6.3% |
| 2016 Q3 | 390.64 Million USD | 23.36% |
| 2015 Q3 | 413.09 Million USD | 14.7% |
| 2015 FY | - USD | 49.32% |
| 2015 Q1 | 299.58 Million USD | 21.11% |
| 2015 Q2 | 360.15 Million USD | 20.22% |
| 2015 Q4 | 231.08 Million USD | -44.06% |
| 2014 Q4 | 247.36 Million USD | 25.74% |
| 2014 FY | - USD | 10.32% |
| 2014 Q1 | 197.46 Million USD | -6.89% |
| 2014 Q2 | 235.42 Million USD | 19.22% |
| 2014 Q3 | 196.72 Million USD | -16.44% |
| 2013 Q4 | 212.07 Million USD | -14.35% |
| 2013 FY | - USD | 66.05% |
| 2013 Q3 | 247.6 Million USD | 47.56% |
| 2013 Q2 | 167.8 Million USD | 3.29% |
| 2013 Q1 | 162.45 Million USD | 11.52% |
| 2012 FY | - USD | 323.1% |
| 2012 Q4 | 145.67 Million USD | -31.19% |
| 2012 Q1 | 30.61 Million USD | 181.7% |
| 2012 Q2 | 96.89 Million USD | 216.47% |
| 2012 Q3 | 211.69 Million USD | 118.48% |
| 2011 Q1 | -40.98 Million USD | -220.74% |
| 2011 Q4 | -37.47 Million USD | 25.32% |
| 2011 Q2 | -52.41 Million USD | -27.91% |
| 2011 FY | - USD | -110.48% |
| 2011 Q3 | -50.18 Million USD | 4.27% |
| 2010 Q2 | -19.79 Million USD | 30.94% |
| 2010 FY | - USD | -62.84% |
| 2010 Q3 | -27.65 Million USD | -39.72% |
| 2010 Q4 | -12.77 Million USD | 53.8% |
| 2010 Q1 | -28.65 Million USD | 16.87% |
| 2009 Q1 | -18.25 Million USD | -4.94% |
| 2009 Q2 | -17.59 Million USD | 3.63% |
| 2009 Q3 | -1.29 Million USD | 92.66% |
| 2009 Q4 | -34.47 Million USD | -2570.26% |
| 2009 FY | - USD | 33.37% |
| 2008 FY | - USD | 27.48% |
| 2008 Q4 | -17.39 Million USD | 16.45% |
| 2008 Q3 | -20.82 Million USD | -3.85% |
| 2008 Q2 | -20.05 Million USD | 1.07% |
| 2008 Q1 | -20.26 Million USD | -100.52% |
| 2007 Q3 | -41.64 Million USD | -20.47% |
| 2007 Q4 | -10.1 Million USD | 75.73% |
| 2007 FY | - USD | -13.0% |
| 2007 Q2 | -34.57 Million USD | 7.9% |
| 2007 Q1 | -37.53 Million USD | -24.75% |
| 2006 Q4 | -30.09 Million USD | -22.57% |
| 2006 FY | - USD | -210.83% |
| 2006 Q3 | -24.54 Million USD | -19.41% |
| 2006 Q2 | -20.55 Million USD | -15.08% |
| 2006 Q1 | -17.86 Million USD | -108.11% |
| 2005 Q3 | -33.19 Million USD | 9.08% |
| 2005 FY | - USD | 463.35% |
| 2005 Q2 | -36.51 Million USD | 29.39% |
| 2005 Q1 | -51.71 Million USD | -953.62% |
| 2005 Q4 | 220.32 Million USD | 763.68% |
| 2004 Q1 | -16.3 Million USD | -19.09% |
| 2004 FY | - USD | 70.26% |
| 2004 Q4 | 6.05 Million USD | 186.3% |
| 2004 Q3 | -7.02 Million USD | 29.45% |
| 2004 Q2 | -9.95 Million USD | 38.98% |
| 2003 Q2 | -26.93 Million USD | 7.12% |
| 2003 Q4 | -12.82 Million USD | 41.31% |
| 2003 FY | - USD | 25.56% |
| 2003 Q3 | -22.04 Million USD | 7.98% |
| 2003 Q1 | -26.09 Million USD | 20.46% |
| 2002 Q2 | -27.72 Million USD | -16.65% |
| 2002 Q1 | -23.18 Million USD | 14.82% |
| 2002 Q3 | -30 Million USD | -6.96% |
| 2002 Q4 | -32.58 Million USD | -5.98% |
| 2002 FY | - USD | -33.96% |
| 2001 Q3 | -21.77 Million USD | -24.93% |
| 2001 FY | - USD | -463.67% |
| 2001 Q1 | -13.38 Million USD | -999.02% |
| 2001 Q2 | -16.66 Million USD | -61.87% |
| 2001 Q4 | -27.78 Million USD | -22.18% |
| 2000 Q3 | -14.33 Million USD | -19.65% |
| 2000 Q2 | -2.83 Million USD | 53.75% |
| 2000 FY | - USD | 23.93% |
| 2000 Q1 | -7.55 Million USD | -1354.29% |
| 2000 Q4 | -8.21 Million USD | 76.91% |
| 1999 Q1 | -9.7 Million USD | -46.77% |
| 1999 FY | - USD | -52.86% |
| 1999 Q4 | 200 Thousand USD | 115.91% |
| 1999 Q3 | -4.2 Million USD | 46.34% |
| 1999 Q2 | -7.5 Million USD | 9.89% |
| 1998 FY | - USD | -4766.67% |
| 1998 Q3 | -1.7 Million USD | -200.0% |
| 1998 Q4 | -5.5 Million USD | -121.43% |
| 1998 Q1 | -4 Million USD | -275.86% |
| 1998 Q2 | 1.5 Million USD | 154.9% |
| 1997 Q3 | -100 Thousand USD | 130.0% |
| 1997 Q1 | -2.9 Million USD | -271.43% |
| 1997 FY | - USD | -90.32% |
| 1997 Q4 | 2.3 Million USD | 383.33% |
| 1997 Q2 | -2.5 Million USD | -66.67% |
| 1996 Q2 | -2.2 Million USD | 450.0% |
| 1996 Q4 | -2.9 Million USD | -50.0% |
| 1996 Q1 | -3.2 Million USD | -111.43% |
| 1996 FY | - USD | -76.15% |
| 1996 Q3 | -2.9 Million USD | 0.0% |
| 1995 FY | - USD | 152.0% |
| 1995 Q4 | -1.4 Million USD | -5.41% |
| 1995 Q3 | -800 Thousand USD | 23.33% |
| 1995 Q2 | 200 Thousand USD | 150.0% |
| 1995 Q1 | -500 Thousand USD | 130.77% |
| 1994 Q2 | -9 Million USD | 5.26% |
| 1994 Q4 | -3.9 Million USD | -50.0% |
| 1994 FY | - USD | 29.97% |
| 1994 Q3 | -2.6 Million USD | 71.11% |
| 1994 Q1 | -9.5 Million USD | 7.77% |
| 1993 Q2 | -9.1 Million USD | -15.29% |
| 1993 Q4 | -10.3 Million USD | -21.18% |
| 1993 Q3 | -8.5 Million USD | 13.27% |
| 1993 FY | - USD | -119.02% |
| 1993 Q1 | -8.5 Million USD | -54.55% |
| 1992 Q3 | -5.1 Million USD | -70.0% |
| 1992 Q1 | -2.8 Million USD | 44.0% |
| 1992 FY | - USD | -16.43% |
| 1992 Q4 | -5.5 Million USD | -7.84% |
| 1992 Q2 | -3 Million USD | -7.14% |
| 1991 Q1 | 2 Million USD | 128.57% |
| 1991 Q3 | -2.3 Million USD | -24.24% |
| 1991 Q4 | -3.4 Million USD | -21.95% |
| 1991 FY | - USD | -366.67% |
| 1991 Q2 | -1.8 Million USD | -265.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q4 | -7 Million USD | -638.46% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 2953.289% |
| Dynavax Technologies Corporation | 9.66 Million USD | -48050.217% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -4636.521% |
| Perrigo Company plc | 646.2 Million USD | -620.241% |
| Illumina, Inc. | -608 Million USD | 865.493% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 56.906% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 1136.54% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 141.268% |
| IQVIA Holdings Inc. | 3.25 Billion USD | -42.942% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 4584.161% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 12583.437% |
| Waters Corporation | 1.02 Billion USD | -355.289% |
| Biogen Inc. | 2.37 Billion USD | -95.801% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 5423.527% |
| Evolus, Inc. | -41.81 Million USD | 11231.787% |
| Adicet Bio, Inc. | -136.53 Million USD | 3508.796% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 4055.971% |
| bluebird bio, Inc. | -167.16 Million USD | 2884.262% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 3200.568% |
| FibroGen, Inc. | -261.4 Million USD | 1880.456% |
| Agilent Technologies, Inc. | 1.67 Billion USD | -177.531% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 10573.775% |
| Homology Medicines, Inc. | -47.75 Million USD | 9845.791% |
| Geron Corporation | -174.78 Million USD | 2762.86% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 2140.233% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 5154.573% |
| Myriad Genetics, Inc. | -67.8 Million USD | 6964.602% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4716.025% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 1019.23% |
| Zoetis Inc. | 3.68 Billion USD | -26.301% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 9303.116% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -299.829% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -1399.981% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | -1.064% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 12998.952% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 2123.477% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1849.719% |
| Verastem, Inc. | -83.16 Million USD | 5696.277% |
| Nektar Therapeutics | -243.1 Million USD | 2014.466% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 2168.616% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 5389.765% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 1159.709% |
| OPKO Health, Inc. | -65.51 Million USD | 7203.914% |
| Exelixis, Inc. | 196.6 Million USD | -2267.321% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -1018.529% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -4196.555% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 8447.442% |
| uniQure N.V. | -253.1 Million USD | 1938.878% |
| Imunon, Inc. | -20.78 Million USD | 22495.046% |
| Blueprint Medicines Corporation | -474.61 Million USD | 1080.633% |
| Insmed Incorporated | -654.73 Million USD | 810.848% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -929.811% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 1447.228% |
| TG Therapeutics, Inc. | 26.1 Million USD | -17732.184% |
| Incyte Corporation | 919.42 Million USD | -406.207% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 1021.077% |